Ralf Angermund

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

Maria Teresa Petrucci, Pilar Giraldo, Paolo Corradini et al. · British Journal of Haematology · 2013 · 123 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

Meletios Α. Dimopoulos, Meral Beksaç, Lotfi Benboubker et al. · Haematologica · 2013 · 39 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial

Stefanie Huhn, Niels Weinhold, Jolanta Nickel et al. · Bone Marrow Transplantation · 2017 · 36 citations · Full text

Medicine, Hematology, Oncology +16

Increased Hemoglobin Levels and Improved Quality-of-Life Assessments During Epoetin Alfa Treatment in Anemic Cancer Patients: Results of a Prospective, Multicenter German Trial

Uwe E. Reinhardt, A.H. Tulusan, Ralf Angermund et al. · The Oncologist · 2005 · 16 citations

Medicine, Oncology, Pharmacology +12

Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study

Albert Oriol, Pilar Giraldo, Ιoannis Kotsianidis et al. · Hematology · 2014 · 15 citations

Medicine, Pharmacology, Pharmacotherapy +15